Translational studies of new treatments for movement disorders, including phase II and phase IIII clinical studies.
Neuropharmacology. 2018 Jun 01;:
Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
Parkinsonism Relat Disord. 2018 May 05;:
Curr Opin Neurol. 2018 May 08;:
Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden.
Front Aging Neurosci. 2018;10:120
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Mov Disord. 2018 Mar 23;:
Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.
CMAJ. 2018 Jan 15;190(2):E50-E52
Can J Neurol Sci. 2018 Jan;45(1):23-29
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Neuropharmacology. 2017 Nov 29;:
Mov Disord. 2017 Nov 13;:
Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380